Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Stories That Shocked the BioPharma World in 2018

The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.

Read More »

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

The FDA issued draft guidance for biopharma companies on developing therapies for NASH with liver fibrosis.

Read More »

Top Predictions for 2019 by Biopharma Execs

Biopharma executives were asked to predict what the next year might reveal.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Novo Nordisk hires AstraZeneca executive

Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.

Read More »

Global Biopharma Companies Top Forbes’ List of World’s Best Employers

Forbes’ 2018 ranking of the “World’s Best Employers” includes a number of global biopharmaceutical companies.

Read More »

U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study

A Cuban-developed lung cancer treatment combined with Bristol-Myers Squibb’s anti-PDL1 Opdivo shows promise in treating patients who would not likely benefit from immune checkpoint inhibition.

Read More »

Samsung Bioepis’ Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for U.S. FDA Review

Samsung Bioepis Co. Ltd. announced that the U.S. Food and Drug Administration accepted for review the company’s Biologics License Application under the 351(k) pathway for SB5, a biosimilar candidate referencing Humira (adalimumab).

Read More »

CDC: 14 Million Americans Will Have Alzheimer’s by 2060

Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.

Read More »

FDA Lifts Partial Clinical Hold for Mersana’s XMT-1522

Mersana Therapeutics Inc. announced that the U.S. Food and Drug Administration lifted the partial clinical hold on the Phase 1 study of the experimental cancer drug XMT-1522.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom